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IL-6 is a multifaceted pleiotropic cytokine, which is produced by a variety of cell types and targets different cells and tissues. In
physiological conditions, IL-6 can be locally and transiently produced by skeletal muscle and plays an important role in muscle
homeostasis. Circulating IL-6 levels are normally very low or undetectable but are dramatically increased in several pathologic
conditions. In this study, we aimed to define the potential molecular mechanisms underlying the effects of IL-6 on myogenic
program.We explored the molecular mechanisms through which exogenous IL-6, or the conditioned medium from the murine C-
26 adenocarcinoma cells (a cellular model that secretes high levels of IL-6 and induces cancer cachexia in mice), interferes with the
myogenic program. Our study revealed that IL-6 induces the activation of the Stat3 signaling and promotes the downmodulation
of the p90RSK/eEF2 andmTOR/p70S6K axes, while it does not affect the activation of AKT.We thus identified potential molecular
mediators of the inhibitory effects of IL-6 on myogenic program.
1. Introduction
Muscle differentiation is a well-coordinated and regulated
process which is influenced by either positive or negative
external signals. Fibroblast growth factor (FGF) and TGF-𝛽
inhibit differentiation [1, 2], whereas IGFs are potent inducers
of myogenic proliferation, differentiation, and hypertrophy
[3, 4].
Moreover, several cytokines and other factors, such as IL-
1, IL-6, TNF-𝛼, and IFN-𝛾, have been proven to negatively
affect muscle differentiation both in vitro and in vivo, causing
also muscle wasting [5–8]. Elevated levels of cytokines,
associatedwith chronic inflammation, are observed in several
chronic diseases, ranging from cancer to AIDS and from
muscular dystrophy to chronic heart failure and kidney
disease.
Among these factors, IL-6 potentially plays a prominent
role in muscle differentiation, homeostasis, and wasting.
IL-6 can be produced locally, by skeletal muscle, or
released systemically in response to different physiopatho-
logic stimuli [9]. In skeletal muscle IL-6 acts as a pleiotropic
factor and appears to have at least two different conflicting
functions. In nonpathological conditions, IL-6 has been
involved in the physiological metabolic response of skeletal
muscle to exercise [9, 10]; it is synthesized by skeletal muscle,
in response to increased workload, and secreted locally or
into the blood stream, where it might act in a hormone-
like manner, stimulating the hepatic gluconeogenesis and
increasing adipose tissue lipolysis [10]. It has been also shown
that the autocrine production of IL-6 can promote myo-
genic differentiation [11, 12] and acts as a positive regulator
of satellite cell-mediated hypertrophic muscle growth [13],
suggesting that IL-6 plays an important role in myogenesis.
By contrast, different pathologic conditions promoting
musclewasting, including cancer, are associatedwith elevated
systemic levels of IL-6 [4]. Moreover, severe muscle atrophy
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is seen in different mouse models in which IL-6 has been
chronically elevated in skeletal muscle, through transgenic
overexpression [14], in vivo electroporation [15], or direct
infusion into muscle [16]. The different and opposite effects
of a single molecule, like IL-6, can be explained taking into
consideration the levels of expression and its spatial and
temporal interaction with the target tissue. The regulation of
muscle differentiation is dependent on the activation of signal
transduction cascades with the complex involvement of sev-
eral kinases, including the mitogen-activated protein kinases
(MAPK), the serine/threonine kinase AKT, a downstream
effector of PI3-kinase, the p90 ribosomal S6 kinase (p90RSK),
and the calcineurin/NFAT pathway [17].
In this study, we explored some molecular mechanisms
through which exogenous IL-6 can perturb the skeletal
muscle homeostasis and impinge muscle differentiation.
We treated C2C12 myogenic cells, an in vitro model able
to recapitulate the program of myogenic differentiation with
recombinant IL-6 or with the conditioned medium from the
C-26 mouse adenocarcinoma cell line (C-26 CM), which
secrete IL-6 in the extracellularmedium (as it is shown in this
paper and in [5, 18]). We show that IL-6 induced a dramatic
inhibition in the expression of late myogenic differentiation
markers, such as myogenin and sarcomeric muscle myosin,
whereas it did not significantly affect the expression of Pax7
and MyoD. IL-6 also did not affect the activation of AKT, a
kinase essential to promote protein synthesis and cell survival
and to block protein degradation [19, 20]. However, we show
that exogenous IL-6 induced a selective downmodulation
of the p90RSK/eEF2 and mTOR/p70S6K axes, which are
important mediators for the positive control of protein
synthesis and themaintenance of the differentiatedmyogenic
phenotype [19, 21–23].
2. Material and Methods
2.1. Cell Culture and Media Preparation. Murine C2C12
myoblasts cells and C-26 colon adenocarcinoma (ATCC)
were grown inDulbecco’smodified Eagle’s medium (DMEM)
with 10% fetal bovine serum plus standard complements
(growth medium, GM). To induce myogenic differentia-
tion of C2C12 myoblasts, cells were cultured in GM until
subconfluence (i.e., about 80–90% of cell confluence) and
then shifted to DMEM with 2% horse serum (differentiation
medium, DM). All media, sera, and complements for cell
cultures were from Gibco-Invitrogen. For C-26 conditioned
medium (CM) production, about 8 × 105 C-26 cells were
plated in GM in a 60 × 15mm cell culture dish (Falcon).
After the overnight attachment, the medium was totally
replaced with 6mL of fresh GM. When the C-26 cells
reached confluence, the resulting medium (C-26 CM) was
collected, centrifuged (1000 g for 10min), and filtered with
a 0.22𝜇m polyethersulfone hydrophilic filter (Millipore). 2%
horse serum (final concentration) was added to C-26 CM,
which was finally diluted in a ratio 1 : 10 in the DM, to obtain
the DM + 10% C-26 CMmedium.
Recombinantmouse IL-6 (rIL-6) was fromR&DSystems.
Lyophilized rIL-6 was dissolved at 100 𝜇g/mL in sterile PBS
containing 0.1% bovine serum albumin (BSA, globulin-free
and low endotoxin, purity ≥98%, from Sigma). rIL-6 was
diluted into DM to obtain the (DM + 25 ng/mL of rIL-6)
medium. The same amount of carrier BSA was added in
the control DM. However, previous analysis showed that the
carrier BSA did not interfere with myogenic differentiation
(data not shown).
2.2. Cytokine Assay. TheBDBiosciences CBAMouse Inflam-
mation Kit was used to quantitatively measure IL-6, IL-
10, MCP-1, IFN-𝛾, TNF-𝛼, and IL-12p70 protein levels,
according to the manufacturer instructions. In brief, 50 𝜇L of
supernatants (C-26 CM or control samples) were incubated
with a mixture of beads coated with the capture antibodies
for the different cytokines. Addition of the PE-conjugated
detection antibodies formed a sandwich complex. After 2 h
of incubation and one wash, samples were analyzed by flow
cytometry, using an Epics XL Cytometer (Beckman Coulter).
Standard curves were generated from analysis of titrated
cytokine standards (at least 10 serial dilutions; standards
provided by the manufacturer) and analysis was performed
using the BD CBA analysis software.
2.3. Immunohistochemical Analysis. C2C12 myotubes were
fixed in 4% paraformaldehyde and then preincubated in
phosphate-buffered saline (PBS) containing 1% BSA and a
1 : 30 dilution of goat serum for 30min. Myotubes were
treated with a monoclonal antibody against the anti-myosin
type II (MF-20, Developmental Studies Hybridoma Bank)
(1 : 100, overnight at 4∘C). After incubation with the primary
antibody, themyotubes werewashed twicewith PBS and once
with PBS containing 1% BSA for 15min and incubated with
goat anti-mouse rhodamine-conjugated secondary antibody.
The cells were washed again, as described above, and the
nuclei of myogenic cells were visualized by Hoechst staining.
Finally the slidesweremounted in 90%glycerol in PBS (pH8)
and visualized under inverted microscope (Axioskop 2 plus;
Carl Zeiss MicroImaging, Inc.) and images were processed
using Axiovision 3.1.
2.4. Protein Extraction and Immunoblotting. C2C12 cells
were washed with PBS and lysed in RIPA buffer (radio
immunoprecipitation assay buffer) (100mM Tris/HCl pH
7.4, 150mM NaCl, 20mM sodium fluoride, 2mM EDTA,
0.2mM 2-glycerophosphate, 1mM sodium vanadate, 3%
(w/v) deoxycholate, 10mM Na
4
P
2
O
7
, 0.5% SDS, and 1%
(v/v) Nonidet P40) containing a protease inhibitor cock-
tail (Complete Mini, Roche). Cells were sonicated and
cleared by centrifugation (10,000 g for 10min, at 4∘C), and
the whole cell lysate supernatant was collected. Proteins
were resolved by SDS/PAGE, transferred on to Protran
nitrocellulose membranes (Whatman), and immunoblotted
under standard conditions, with primary antibodies as fol-
lows: anti-myosin type II MF-20 (Developmental Studies
Hybridoma Bank); anti-𝛼-tubulin (Sigma); anti-phospho-
Stat3 (Tyr705) D3A7 (Cell Signaling Technology); anti-Stat3
D3Z2G (Cell Signaling); anti-phospho-AKT (Ser473) D9E
(Cell Signaling); phospho-Akt (Thr308) (D25E6); anti-AKT
(Cell Signaling); anti-phospho-mTOR (Ser2448) D9C2 (Cell
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Signaling); anti-mTOR (Cell Signaling); anti-phospho-p70S6
kinase (Thr389) 108D2 (Cell Signaling); anto-phospho-p70
S6 Kinase (Ser371) (Cell Signaling); anti-p70S6 Kinase (Cell
Signaling); anti-phospho-p90RSK (Thr359/Ser363) (Cell Sig-
naling); anti-pan p90RSK number 9347 (Cell Signaling);
anti-eEF2 (Thr56) (Cell Signaling); and anti-eEF2 (Cell
Signaling). Anti-mouse or anti-rabbit immunoglobulin G
horseradish peroxidase linked F(ab󸀠)2 secondary antibodies
and enhanced chemiluminescence detection kit were from
Amersham Biosciences.
2.5. RNA Isolation, RT (Reverse Transcription), and Real Time
PCR. C2C12 cells were washed with ice-cold PBS and total
RNA was extracted using the TRIzol reagent (Life Tech-
nologies). Digestion of contaminating genomic DNA was
performed with DNA-free DNase treatment (Ambion). First
strand cDNA was generated using a kit with random primers
(High Capacity cDNA Reverse Transcription kit, Applied
Biosystems) from 1𝜇g of total RNA.Newly synthesized cDNA
was diluted 5-fold in DNA-free water and 5% of this cDNA
was used in each real-time PCR assay, using a 7500 Real
Time PCR System (Applied Biosystems). The standard curve
method was used to calculate the relative mRNA levels for
each transcript examined and actin beta (ACTB) was used
as a reference to normalize the data. Specific assays used
for the Taqman quantification were all from Applied Biosys-
tems: MYOG: Mm00446195 g1; MYOD1: Mm01203489 g1;
PAX-7: Mm01354484 m1; SOCS3: Mm00545913 s1; ACTB:
Mm00607939 s1.
2.6. Densitometric Analysis and Statistics. Densitometry was
performed on scanned immunoblot images (Aida 2.11 soft-
ware). The gel analysis tool was used to obtain the absolute
intensity (AI) for each experimental band and corresponding
control band. Relative intensity (RI) for each experimen-
tal band was calculated by normalizing the experimen-
tal AI to the corresponding control AI. In both densito-
metric analysis and real-time PCR analysis, the software
GraphPad Prism was used to perform statistical analysis
with Student’s 𝑡-test. Results are expressed as means ±
s.e.; 𝑃 values <0.05 were considered statistically signifi-
cant.
3. Results
3.1. C-26 Adenocarcinoma Cells Secrete IL-6. Proinflamma-
tory cytokines might impinge muscle differentiation both in
vitro and in vivo [6–8]. We measured the concentration of
IL-6, IL-10, TNF-𝛼, MCP-1, INF-𝛾, and IL-12p70 secreted
in the conditioned medium (CM) by the murine colon C-
26 adenocarcinoma cells [5, 18]. This quantitative analysis
revealed that C-26 cells secreted and progressively accumu-
lated, in CM, relatively high concentrations of two cytokines,
IL-6 and MCP-1 (Figure 1). The levels of the other cytokines
secreted in CM by C-26 cells, such as INF-𝛾, IL-10, TNF-𝛼,
and IL-12, were not significantly different compared with the
control medium obtained from the C2C12 myogenic cell line
(Figure 1).
3.2. C-26 Conditioned Medium Inhibits C2C12 Myogenic Dif-
ferentiation. In agreement with previously published exper-
iments [24], we observed that when C-26 CM was added to
the standard growth medium, C2C12 myoblasts proliferation
was impaired (data not shown). To explore if the factors
secreted by C-26 adenocarcinoma cells were able to directly
interfere with muscle differentiation, we let proliferate C2C12
myoblasts in the standard growth medium until about 80–
90% of cell confluence (subconfluence) and then we shifted
the cells to the differentiation medium (DM) containing 10%
C-26 CM (Figure 2(a)).
Morphological and immunofluorescence analysis re-
vealed that the presence of C-26 CM in DM induced a
significant reduction in the number and size of the myosin
positive multinucleated myotubes, compared with control
C2C12 myotubes (Figure 2(a)). The altered differentiated
muscle phenotype was also confirmed by Western blot
analysis, revealing a drastic downmodulation of the sarco-
meric myosin heavy chain expression, a specific marker of
myogenic differentiation (Figures 2(b) and 2(c)).
Our results demonstrate that factors released in the
extracellular medium by C-26 adenocarcinoma cells were
able to interfere, in a cell autonomous manner, with C2C12
myogenic differentiation and maturation.
3.3. IL-6 Negatively Regulates C2C12 Myogenic Differentia-
tion. Previous studies have shown that C-26 conditioned
medium is a complex mixture of secreted proteins, including
cytokines, growth factors, and signaling molecules, some of
which can potentially play a role in myogenic program and
muscle wasting [5, 24]. In this work, using a proinflammatory
cytokine array, we have shown that adenocarcinoma C-26
cells can secrete and progressively accumulate in the CM
high concentrations of at least two cytokines, IL-6 andMCP-1
(Figure 1).
We explored if IL-6 can recapitulate the inhibitory effect
of C-26 CM on C2C12 myogenic differentiation or whether
this inhibition is the sum of the concomitant effects of several
tumoral factors secreted by C-26 cells.
To avoid any confounding effect, we induced C2C12
myogenic differentiation in the presence of the differentia-
tion medium (DM) supplemented with recombinant exoge-
nous IL-6 protein (rIL-6). We then analysed the differ-
entiated myotubes by Western blotting and immunofluo-
rescence analysis (Figure 2). We observed that the C2C12
myotubes treated with rIL-6 were shorter and smaller in
size (Figure 2(a)) and displayed a significant reduction in the
sarcomeric myosin heavy chain expression compared with
the myotubes differentiated in the control medium (DM)
(Figures 2(b) and 2(c)).
Of note, the inhibitory effects of rIL-6 and C-26 CM on
C2C12 myogenic differentiation were similar (Figures 2(a)–
2(c)).
We also analyzed, by real-time PCR, the effects of rIL-
6 on the expression of Pax-7 and MyoD1, two transcription
factors that are expressed prevalently in the proliferating
myoblasts and in the early stages of the myocytes differen-
tiation [25], and of myogenin, a molecular marker associated
4 BioMed Research International
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Figure 1: Determination of secreted cytokines in the conditioned medium from C-26 adenocarcinoma cells. (a–f) MCP-1, IL-6, IFN-𝛾, IL-
10, TNF-𝛼, and IL-12p70 protein levels were measured using a cytometric bead assay in which the specific antibodies were conjugated with
capture beads (see Section 2).MCP-1 concentration is expressed in ng/mL, whereas the other cytokines concentrations are in pg/mL. 1: control
I, conditioned medium (CM) from proliferating C2C12 cells in growth medium (GM); 2: control II, myogenic differentiation medium (DM);
3: CM from proliferating C-26 cells in GM (i.e., exponential phase, with a cell confluence about 50%); 4, 5, and 6: CM from confluent C-26
cells (i.e., stationary phase) with a cell confluence of about 100% for 1, 2, or 3 days, respectively. The experiment indicates means ± standard
deviation from three independent determinations.
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Figure 2: C-26 CM and exogenous IL-6 impair the myogenic differentiation of C2C12 cells. C2C12 myoblasts were cultured in GM
until subconfluence and then shifted to differentiation medium (DM), or DM containing 10% C-26 CM, or DM containing 25 ng/mL of
recombinant IL-6. (a) After 48 h in the differentiation media, cells were stained using an anti-sarcomeric myosin heavy chain (MF-20)
antibody (red) and the Hoechst staining of the DNA (blue) and was imaged by conventional fluorescent microscopy. (b) After 48 h in the
differentiation media, cells were harvested and total protein was extracted; cell lysates (70 𝜇g of total protein) were subjected to Western
blot analysis with the indicated specific antibodies. The experiment shown is representative of three independent determinations. (c)
Densitometric analysis of the relative protein levels (obtained fromWestern blotting analysis) of sarcomeric myosin heavy chain, represented
as arbitrary units (A.U.) and equalized for 𝛼-tubulin expression. ∗∗∗𝑃 < 0.005 (Student’s 𝑡-test).
with the myocytes’ full commitment to differentiation [25]
(Figure 3). rIL-6 did not induce any significant change in
Pax7 and MyoD expression (Figures 3(a) and 3(b)), whereas
we observed a significant downregulation of the myogenin
expression compared with controls (Figure 3(c)). On the
whole, these data show that exogenous rIL-6 negatively
regulatesC2C12myogenic differentiation,without interfering
with the early stage of the myogenic program.
3.4. Exogenous IL-6 Activates Stat3-SOCS3 Signaling during
C2C12 Myogenic Differentiation. Skeletal muscle expresses
the IL-6 receptor (IL6R/CD126) and it is a target of the IL-
6 activity [10]. Binding of IL-6 to its receptor initiates specific
intracellular events, including phosphorylation and activa-
tion of the Janus kinases (JAK) and the subsequent activation
of the signal transducer and activator of transcription (Stat)
[26, 27]. IL-6-induced Stat signaling also initiates a negative
feedback regulation through the increased transcription of
the suppressor of cytokine signaling (SOCS) proteins [27].
We analyzed whether rIL-6 treatment activates the
canonical signaling through the IL-6 receptor. To this
purpose, we induced C2C12 myogenic differentiation in
the presence of the differentiation medium (DM) supple-
mented with rIL-6. Western blot analysis showed that rIL-
6 treatment elicited a significant upregulation of the active
phosphorylated form (on the Tyr 705 residue) of Stat3
(phospho-Stat3) at the early stages of myogenic differentia-
tion (i.e., day 1; Figure 4(a)), whereas rIL-6 did not induce
significant changes in phospho-Stat3 at later stages of the
myogenic differentiation (i.e., day 2 and later; Figure 4(a) and
data not shown). Real-time PCR analysis showed that the
expression of SOCS3 (the suppressor of the IL-6 signaling)
was induced by rIL-6 treatments only at the late stage of the
myogenic differentiation (i.e., day 2 and later; Figure 4(b) and
data not shown).
In conclusion, this experiment shows that in C2C12 cells
the exogenous rIL-6 is able to efficiently activate the Stat3-
SOCS3 signaling during myogenic differentiation; moreover,
the cytokine-inducible positive activation of Stat3 takes place
at the early stages of myogenic differentiation, whereas the
negative feedback of the signaling pathway (promoted by the
Stat signaling itself) is activated at later differentiation stages,
through the transcriptional induction of SOCS3.
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Figure 3: Exogenous IL-6 impairs the expression of myogenin, without affecting the expression of Pax-7 and MyoD. C2C12 myoblasts were
cultured in GMuntil subconfluence and then shifted to DMorDM containing 25 ng/mL of recombinant IL-6. After 48 h in the differentiation
media, cells were harvested, total RNA was extracted, and first-strand cDNAwas generated from 1 𝜇g of total RNA to perform real-time PCR
using specific Taqman probes. Expression data were normalized using actin beta (ACTB) as housekeeping gene. Results are expressed as
means ± standard deviations. ∗∗𝑃 < 0.005; n.s., not significant (Student’s 𝑡-test).
3.5. Exogenous IL-6 Perturbs mTOR and p70S6K Activities,
without Affecting AKT Activity, during C2C12 Myogenic Dif-
ferentiation. AKT inhibition can substantially contribute to
impinge muscle differentiation and muscle atrophy [19, 20,
28]. AKT plays a central role in the control of both muscle
protein synthesis, viamTOR, and protein degradation, via the
transcription factors of the FoxO family [19, 20].
Thus, we analyzed if exogenous rIL-6 could perturb
AKT signaling pathways during C2C12 myogenic differen-
tiation. We induced C2C12 differentiation in the presence
of DM supplemented with rIL-6 and then analyzed the
differentiated myotubes by Western blotting using specific
antibodies (Figure 5). In the C2C12 myotubes differentiated
in the presence of rIL-6 we did not observe any significant
change in the levels of both the total AKT protein and the
phosphorylated/active forms of AKT, namely, phospho-AKT
Thr308 and phospho-AKT Ser473 (Figures 5(a)–5(d)). How-
ever, rIL-6 induced a significant reduction in the phosphory-
lated/active forms of mTOR (phospho-Ser2448) and p70S6K
(phospho-Thr389 and phospho-Ser371) (Figures 5(e)–5(i)).
The 2 kinases mTOR and p70S6K are among the crucial
downstream effectors of the AKT pathway and positively
control protein synthesis and muscle differentiation [29].
In conclusion, this experiment shows that, during C2C12
myogenic differentiation, AKT does not sustain alone the
activity of mTOR and p70S6K1. We suggest that an ancillary
pathway should contribute to sustain the activity of mTOR
and p70S6K during C2C12 myogenic differentiation and
when this ancillary pathway is inhibited, by exogenous rIL-
6, the activation of mTOR and p70S6K is perturbed and the
myotubes formation is impaired (see Figures 2 and 5).
3.6. Exogenous IL-6 Affects the Phosphorylation Levels of
p90RSK and eEF2 during C2C12 Myogenic Differentiation.
It has been demonstrated that, similar to AKT, signaling
generated from p90RSK plays a positive role in the regulation
of protein synthesis during myogenic differentiation and
maturation [21, 22]. Active p90RSK increases the levels of
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Figure 4: Exogenous IL-6 activates Stat3-SOCS3 signaling during myogenic differentiation. C2C12 myoblasts were cultured in GM until
subconfluence and then shifted to DM or DM containing 25 ng/mL of recombinant IL-6. After 24 h or 48 h in the differentiation media, cells
were harvested and total protein was extracted, or total RNA was extracted and first-strand cDNA was generated from 1𝜇g of total RNA. (a)
Cell lysates (70 𝜇g of total proteins) were subjected toWestern blotting analysis with the indicated specific antibodies.The experiment shown
is representative of three independent determinations. (b) Real-time PCR was performed on cDNA, using the indicated specific Taqman
probes. Expression data were normalized using actin beta (ACTB) as housekeeping gene.The experiment shows means ± standard deviation
of three independent determinations. ∗∗𝑃 < 0.005; n.s., not significant (Student’s 𝑡 test).
the dephosphorylated (active) form of eEF2, which catalyzes
the translocation of peptidyl-tRNA from the A site to the P
site on the ribosome [21]. Moreover, p90RSK can promote
mTOR and p70S6K1 activation independently from AKT
(Figure 6(d) and [23]). Thus, we explored if IL-6 could
perturb p90RSK signaling pathways during C2C12 myogenic
differentiation (Figure 6). We induced C2C12 differentiation
in the presence ofDMsupplementedwith rIL-6. IL-6was able
to induce a negative regulation of p90RSK signaling in the
myogenic cells. As shown in Figures 6(a) and 6(b), p90RSK
phosphorylation/activation was significantly downregulated
in C2C12 differentiating cells treated with rIL6, and the
reduced p90RSK active formwas associated with a significant
increase in the levels of the eEF2 phosphorylation (Figures
6(a)–6(c)), which is involved in the downmodulation of the
translocation step in the protein synthesis [21].
In summary, in this study we suggest that, during C2C12
myogenic differentiation, exogenous rIL-6 can induce a
depression of the protein synthesis in the myotubes, via a
concomitant downmodulation of the p90RSK/eEF2 axis and
of the mTOR/p70S6K, without apparently affecting the AKT
activity.
4. Discussion
There is increasing evidence demonstrating the critical role of
IL-6 in muscle homeostasis, regeneration, and differentiation
[9]. Mouse models in which IL-6 has been locally chronically
elevated in skeletal muscle, through transgenic overexpres-
sion [14], in vivo electroporation [15], or being infused
directly into muscle [16], induced muscle atrophy. Finally,
it has been shown that administration of IL-6 neutralizing
antibodies or IL-6 inhibitors can reduce muscle wasting in
tumor-bearing mice [5, 30].
In this study, we have shown that the murine colon C-26
adenocarcinoma cell line (C-26) secreted in the extracellular
medium significant concentrations of two cytokines, IL-6 and
MCP-1, whereas we could not detect any significant accu-
mulation of other relevant inflammatory cytokines tested,
namely, INF-𝛾, IL-10, TNF-𝛼, and IL-12 (Figure 1).
The accumulation of the proinflammatory cytokine IL-
6 in the extracellular medium of the C-26 cancer cells was
not unexpected. Strassmann et al., in fact, reported that
some clones of C-26 adenocarcinoma cells can secrete IL-
6 and linked this cytokine to the development of a severe
cachexia associated with muscle wasting [5]. It has been
shown that mice implanted with the C-26 cells have an
increased circulating IL-6 concentration, which coincides
with muscle wasting [5].
In this study, we found that, in addition to IL-6, C-26 cells
also secreted and accumulated in the extracellular medium
the monocyte chemotactic protein-1 (MCP-1). MCP-1 is a
chemokine and member of the small inducible cytokine
family, playing a crucial role in the recruitment of monocytes
and T lymphocytes into tissues [31]. In nonpathological
conditions MCP-1 is expressed by adipocytes and by a
number of other cell types, including smooth muscle and
endothelial cells exposed to inflammatory stimuli [31]. MCP-
1 has also been shown to play a prominent role as an inducer
of insulin resistance in human skeletal muscle cells [32]. This
latter role of MCP-1 may link directly this cytokine to the
downmodulation of protein synthesis and/or to the increase
in protein degradation and, in this way, to cancer cachexia. In
this paper, we did not tackle the possible implication ofMCP-
1 on myogenic program, which will be addressed in a further
dedicated investigation.
In our study, we aimed to explore the specific effect of IL-
6 on the myogenic program, with the goal to demonstrate
whether IL-6 was able to recapitulate the inhibitory effect
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Figure 5: IL-6 perturbs mTOR and p70S6K activities, without affecting AKT activity. C2C12 myoblasts were cultured in GM until
subconfluence and then shifted toDMorDMcontaining 25 ng/mL of recombinant IL-6. (a, e, and f) After 48 h in theDM, cells were harvested
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(b and c), 𝛼-tubulin expression (d), total p70S6K expression (g and h), or total mTOR expression (i).The experiments showmeans ± standard
deviation of three independent determinations. n.s., not significant; ∗𝑃 < 0.05; ∗∗𝑃 < 0.005 (Student’s 𝑡 test).
of C-26 CM on C2C12 myogenic differentiation or whether
this inhibition required the sum of the concomitant effects
of several factors secreted by C-26 cells. Thus, to avoid
any confounding result, we restricted the analysis to the
proinflammatory cytokine IL-6. We added recombinant IL-
6 (rIL-6) in the differentiation medium (DM) and we found
that this cytokine is able to recapitulate the key inhibitory
effects of C-26 CM on C2C12 myogenic differentiation. The
presence of exogenous recombinant IL-6 in the DM induced
a significant downregulation in the expression of the late
markers of myogenic differentiation, like myogenin and the
sarcomericmyosin heavy chain, whereas it did not induce any
significant change in the expression of transcription factors
that are expressed prevalently in the proliferating myoblasts
and at the early stages of the myocytes differentiation [25]
(Figure 2). This suggests that rIL-6 impinges muscle differ-
entiation without hampering the early stage of the myogenic
program.
We have also shown that the negative effects of rIL-6
on muscle differentiation are apparently mediated by the
canonical activation of the Stat-SOCS signaling pathway
(Figure 4). Our results are in accordance with a context
in which IL-6 can play a prominent role in the cancer-
induced muscle wasting [2, 4, 5, 11]. However, other reports
have shown that in myogenic cells the autocrine production
of IL-6 can also induce Stat3 activation but promotes the
myogenic differentiation [11, 12]. It has been shown that IL-6
mRNA knockdown reduces muscle-specific gene expression
in cultured C2C12 myoblasts [11], suggesting a potential
myogenic role for the cytokine. Moreover, Serrano et al.
identified IL-6 as an essential regulator of satellite cell-
mediated hypertrophic muscle growth [13]. This apparent
paradox can be justified considering the levels of expression
of IL-6, its spatial and temporal interaction with the target
tissue, and the length of time in which the circulating IL-
6 is actually elevated, that is, a chronic response versus a
somewhat brief increase that returns to baseline [33].
Skeletal muscle cells are at the same time a source and a
target of IL-6 [10]. It has been shown that, with exercise and
under physiological conditions, skeletalmuscle-produced IL-
6 can be elevated in the circulation for several hours and
that the autocrine effects of IL-6 contribute to activation
of the Stat3-SOCS3 signaling and to the positive regulation
of the myogenic differentiation [10, 33]. By contrast, under
pathologic conditions, including cancer cachexia, muscular
dystrophy, and chronic inflammatory diseases, there is a
chronic (i.e., long lasting) elevation of the circulating IL-
6; although Stat3-SOCS3 signaling is also activated in the
target skeletal muscle tissue under these pathologic condi-
tions, the autocrine loop of regulation in the action of the
cytokine is totally lost. It is possible that different intracellular
signaling pathways are activated and this may explain why
IL-6 can function both as positive and negative regulator
of the myogenesis in physiological or in pathological condi-
tions.
In skeletal muscle, AKT plays a very central role in the
control of both muscle protein synthesis, via mTOR, and
protein degradation, via the transcription factors of the FoxO
family [19, 29]. However, in this study we found that rIL-6 did
not directly affect AKT expression and activity during C2C12
myogenic differentiation (Figure 5).
Instead, we found that rIL-6 induced the concomitant
downmodulation of two signaling axes which are down-
stream to AKT and are important for the regulation of the
protein synthesis, namely, p90RSK/eEF2 and mTOR/p70S6K
(see Figure 5 and [19, 21, 23, 29]).
In muscle cells, activated p90RSK phosphorylates and
inactivates the elongation factor 2 kinase (eEF2K); inhibition
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Figure 6: IL-6 affects the phosphorylation levels of p90RSK and eEF2. C2C12 myoblasts were cultured in GM until subconfluence and
then shifted to DM or DM containing 25 ng/mL of recombinant IL-6. (a and c) After 48 h in the DM, C2C12 cells were harvested and total
protein was extracted; cell lysates (70 𝜇g of total proteins) were subjected to Western blotting analysis with the indicated specific antibodies.
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model of the signaling connections was highlighted and discussed in this study.
of eEF2K activity results in a decrease in the inhibitory phos-
phorylation of eEF2 [21]. Indeed, only the dephosphorylated
form of eEF2 is active and can catalyze the translocation
of the peptidyl-tRNA from the A site to the P site on the
ribosome and finally promote the protein synthesis [21] (see
Figure 6(d)).
Activated p90RSK1 can also promote the protein syn-
thesis acting on mTOR/p70S6K1 pathway independently of
AKT activation [23] (Figure 6(d)). In fact, p90RSK1 has been
found to interact with and phosphorylate the protein tuberin
in a specific regulatory site and this phosphorylation inhibits
the function of the tuberin-hamartin complex, resulting in
increased mTOR signalling to p70S6K1 [9]. Finally, eEF2K
activity can also be regulated by p70S6K; this latter kinase can
in fact phosphorylate eEF2K and, as p90RSK1, can inhibit its
activity [21].
It is evident that destabilization of this very intricate
network of signaling pathways by the exogenous IL-6 (i.e., by
the chronic elevation of circulating IL-6) can contribute to the
decrease of the muscle protein synthesis and the promotion
of muscle wasting (Figure 6(d)).
Our findings thus identify the p90RSK/eEF2 and
mTOR/p70S6K axes as new potential targets of IL-6 activity
on the myogenic program.
5. Conclusions
This study clarified the possible role of the IL-6 in the induc-
tion of skeletal muscle wasting. We show that rIL-6 impairs
C2C12 myogenic differentiation, activates the Stat3-SOCS3
signaling pathway, and induces the downmodulation of
p90RSK/eEF2 and mTOR/p70S6K axes, which are important
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to stimulate the protein synthesis and in the maintenance
of the differentiated myogenic phenotype. Exogenous rIL-6
does not affect the expression levels and activation of AKT, a
kinase essential to promote protein synthesis and cell survival
and to block protein degradation in skeletal muscle cells.
Moreover, in this study we discuss how the pleiotropic
cytokine IL-6 can contribute to the positive regulation of the
myogenic differentiation under physiological conditions and
to the negative regulation of the myogenic phenotype under
some pathological circumstances.
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